The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Dose-finding study of cilazapril (Inhibace) in patients with uncomplicated essential hypertension.
Cilazapril , an angiotensin converting enzyme ( ACE ) inhibitor with a long half-life , effectively reduced sitting diastolic blood pressure in patients with uncomplicated essential hypertension at dosages of 2.5 , 5.0 , and 10.0 mg/day , evaluated in a double-blind , placebo-controlled study . After a four-week placebo run-in period , 235 patients received either cilazapril or placebo for four weeks . At the end of the treatment period , significant decreases from baseline in sitting diastolic blood pressure were seen in all four groups ( mean decreases of 3.3 mm Hg with placebo and 6.4 , 9.2 and 8.3 mm Hg with 2.5 , 5.0 and 10.0 mg cilazapril , respectively ) . The cilazapril groups had significantly greater blood pressure reductions than did the placebo group ( p less than or equal to 0.02 ) . The 5.0 mg cilazapril dose was significantly more effective than the 2.5 mg dose ( p less than 0.03 ) . The response rate was notably greater in the cilazapril treatment groups than in the placebo group ( placebo , 27.5 % ; 2.5 mg cilazapril , 42.9 % ; 5.0 mg cilazapril 62.5 % ; 10.0 mg cilazapril , 50.0 % ) . Cilazapril was well tolerated at all three dosages
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .